[go: up one dir, main page]

WO1992004464A3 - Monoclonal antibodies against tenascin - Google Patents

Monoclonal antibodies against tenascin Download PDF

Info

Publication number
WO1992004464A3
WO1992004464A3 PCT/US1991/006433 US9106433W WO9204464A3 WO 1992004464 A3 WO1992004464 A3 WO 1992004464A3 US 9106433 W US9106433 W US 9106433W WO 9204464 A3 WO9204464 A3 WO 9204464A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
antibodies against
tenascin
against tenascin
melanomas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006433
Other languages
French (fr)
Other versions
WO1992004464A2 (en
Inventor
Meenhard Herlyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of WO1992004464A2 publication Critical patent/WO1992004464A2/en
Anticipated expiration legal-status Critical
Publication of WO1992004464A3 publication Critical patent/WO1992004464A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention provides monoclonal antibodies that bind to four non-overlapping epitopes on human tenascin. This invention also provides an improved method for determining metastatic potential of melanomas, based on the discovery that metastatic melanomas secrete tenascin.
PCT/US1991/006433 1990-09-05 1991-09-05 Monoclonal antibodies against tenascin Ceased WO1992004464A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57773290A 1990-09-05 1990-09-05
US577,732 1990-09-05

Publications (2)

Publication Number Publication Date
WO1992004464A2 WO1992004464A2 (en) 1992-03-19
WO1992004464A3 true WO1992004464A3 (en) 2004-05-13

Family

ID=24309942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006433 Ceased WO1992004464A2 (en) 1990-09-05 1991-09-05 Monoclonal antibodies against tenascin

Country Status (2)

Country Link
AU (1) AU8547291A (en)
WO (1) WO1992004464A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436132A (en) * 1993-02-13 1995-07-25 Amano Pharmaceutical Co., Ltd. Quantitative determination of tenascin as glioma marker
WO1996008513A1 (en) * 1994-09-16 1996-03-21 The Scripps Research Institute Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making and using same
IT1307864B1 (en) * 1999-04-20 2001-11-19 Istituto Naz Per La Ricerca Su DIAGNOSTIC METHOD FOR THE RECOGNITION OF HUMAN NEOPLASIA THROUGH THE DETERMINATION OF THE CTN-C ISOFORM OF TN-C, FRAGMENTS OF
US20020187100A1 (en) * 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
GB0207224D0 (en) 2002-03-27 2002-05-08 Novartis Forschungsstiftung Tenascin-W compositions and uses thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, Vol. 47, August 1987 R.G. Blasberg et al.: "Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in Vivo: Kinetics and implications for diagnosis and therapy ", *
CANCER RESEARCH, Vol. 50, July 1990 Michael R. Zalutsky et al.: "Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration ", *
Cell, Vol. 47, October 1986 Ruth Chiquet-Ehrismann et al.: "Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis ", *
Cell, Vol. 59, October 1989 J~rg Spring et al.: "Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments ", *
Dialog Informational Service, File 155, Medline 66-90/May, accession no. 06639065, medline accesssion no. 88284065, Inaguma Y et al: "Epithelial induction of stromal "tenascin" in the mouse mammary gland from embryogenesis to carcino- genesis", & Dev Biol (UNITED STATES) Aug 1988, 128, (2) p245-55. *
Int. J. Cancer: Supplement 4, Vol., 1989 Pier Giorgio Natali et al.: "Tenascin: A hexameric adhesive glycoprotein ", *
Journal of Neurochemistry, Vol., 1990 John R. Harper et al.: "Human neuroectoderm-derived cell line secretes fibronectin that shares the HNK-1/10C5 carbohydrate epitope with Neural cell adhesion molecules ", *
Proc. Natl. Acad. Sci., Vol. 84, July 1987 Eleanor J. Mackie et al.: "Tenascin is a stromal marker for epithelial malignancy in the mammary gland ", *
The Journal of Cell Biology, Vol. 108, June 1989 Virginia A. Lightner et al.: "Tenascin/Hexabrachion in Human Skin: Biochemical Identification and Localization by Light and Electron Microscopy ", *

Also Published As

Publication number Publication date
AU8547291A (en) 1992-03-30
WO1992004464A2 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
NL300142I1 (en) Monoclonal antibody against a cytotoxin, hybridoma cell line, which expresses that and method for the preparation of the purified cytotoxin.
IT8319234A0 (en) PROCEDURE FOR THE PRODUCTION OF HUMAN MONOCLONAL ANTIBODIES.
AU564383B2 (en) Monoclonal antibody immunoassay
ES2106195T3 (en) IGG AGLYCOSILATED ANTIBODY ANTI CD3.
FI963004A7 (en) Monoclonal antibodies that stimulate antibody formation
EP0045103A3 (en) Method for the determination of antigens with the aid of two or more monoclonal antibodies
DK0724456T3 (en) CD40 antibodies
AU4042195A (en) Anti-alphaV-integrin monoclonal antibody
IT8320550A0 (en) PERAFFINITY PURIFICATION PROCEDURE IN WHICH MONOCLONAL ANTIBODIES ARE USED.
AU4485493A (en) Method for generating monoclonal antibodies from rabbits
ITRM920457A0 (en) MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF THE HUMAN P-GLYCOPROTEIN.
FI853395A7 (en) Monoclonal antibodies that block gram-negative bacterial endotoxin.
ES551495A0 (en) PROCEDURE FOR OBTAINING A REACTIVE MONOCLONAL ANTIBODY WITH ESPOROZOITE OR MEROZOIT ANTIGENS FROM EIMERIA SPP.
PT840620E (en) IL-8 ANTAGONISTS FOR ASTHMA TREATMENT
WO1992004464A3 (en) Monoclonal antibodies against tenascin
AU1423892A (en) Monoclonal antibodies directed towards mycobacterial antigens
AU2596397A (en) Monoclonal antibody that detects apoptotic antigen
NO20004251D0 (en) Humanized anti-CEA high affinity monoclonal antibodies
DE3785795D1 (en) MONOCLONAL ANTI-HUMAN CANCER ANTIBODIES.
AU3552689A (en) Monoclonal antibody for colorectal carcinoma
NO834535L (en) PROCEDURE FOR AFFINITY CLEANING USING MONOCLONAL ANTIBODIES.
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes
NO894555L (en) MONOCLONAL ANTIBODY THAT SPECIFICALLY RECOGNIZES N-GLYCOLYL TYPE GM2, HYBRIDOM THAT PRODUCES ANTIBODY AND PROCEDURE FOR PRODUCING THE HYBRIDOM.
AU2828795A (en) Monoclonal antibodies for the reduction of anti-xenogeneic immune responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MC MG MN MW NL NO PL RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2,DRAWINGS,REPLACED BY NEW PAGES 1/2-2/2;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA